Victor Chen is a partner in Goodwin’s Private Equity group. Mr. Chen represents private equity sponsors, multinational corporations and institutional investors in their M&A transactions and investments, with a particular focus on Asia cross-border deals. He has extensive experience advising private equity, venture and institutional investors in their Greater China and U.S. transactions, including public and private mergers and acquisitions, securities offerings, financings, PIPEs and auctions in a wide variety of industries.

Mr. Chen’s practice also involves all aspects of corporate advisory work. Mr. Chen has been active in a number of going-private transactions and has advised founders, special committees, private equity sponsors and financial advisers in these transactions.

Prior to joining Goodwin in 2017, Mr. Chen was a partner in the Hong Kong office of Paul Hastings, and previously practiced at Fried Frank and O’Melveny & Meyers.

Areas of Practice
Domaines D’Expertise





Mr. Chen has served as counsel to:

  • FountainVest Partners in connection with its going private acquisition of Chinese online career platform Zhaopin Limited, together with Hillhouse Capital and SEEK International*
  • FountainVest Partners in a number of transactions, including its establishment of a joint venture in China with WME | IMG, a global sports, fashion and entertainment talent management company, together with Sequoia Capital China and Tencent, and its investments in leading China-based businesses, including Meituan-Dianping,, and Codoon*
  • ZQ Capital its acquisition of Angiotech Pharmaceuticals, Inc., a medical device manufacturer, and its $210 million PIPE investment in NYSE-listed Nu Skin Enterprises*
  • Horizons Ventures Limited, the private investment arm of Li Ka-Shing, in its investments in numerous early-stage technology companies based in the U.S. and Canada*
  • Co-investment fund formed by Focus Media and FountainVest Partners in connection with investments in the sports, media and entertainment industries*
  • TOM Group Limited, in their investments in WeLab Holdings (WeLend) and Rubikloud Technologies Inc.*
  • China Media Capital and FountainVest Partners in their investment in the Greater China business of large-screen movie exhibitor IMAX Corp. (awarded “Mid-Cap Deal of the Year” by Asian Venture Capital Journal (2014)) and the sale of their shares in the Hong Kong IPO of IMAX China*
  • the buyer group (including the Carlyle Group, FountainVest Partners, and CITIC Capital Partners) in connection with the US$3.7 billion acquisition of Focus Media, China’s then-largest leveraged buy-out (awarded “Global M&A Deal of the Year: China Private Equity” by The American Lawyer (2014) and “Private Equity Deal of the Year” by IFLR (2014) and China Law & Practice (2013))*
  • LionRock Capital in connection with numerous transactions*
  • Goldman Sachs as financial adviser to the Special Committee of NASDAQ-listed AsiaInfo-Linkage in a US$890 million going-private acquisition led by CITIC Capital Partners*
  • Lazard as financial adviser to the buyer group in its going-private acquisition of NASDAQ-listed Yucheng Technologies Limited*
  • the private equity buyer consortium in its going-private acquisition of China jewelry retailer and distributor NASDAQ-listed LJ International*
  • the Special Committee of NASDAQ-listed CNinsure in connection with a proposed US$950 million going-private transaction involving its chairman and private equity sponsors, including TPG*
  • the independent board of NYSE-listed Acorn International, a China-based TV retailer, in connection with its consideration of an unsolicited partial tender offer by its co-founders*
  • the founder and controlling shareholder of Tiens Biotech Group in a going-private squeeze-out merger transaction*
  • the Special Committee of Board of Directors of NASDAQ-listed Solarfun Power Holdings, a solar cell producer, in connection with its US$370 million sale of a controlling stake to Hanwha Corporation*
  • Sequoia Capital, Citic Capital and FountainVest Partners in a US$180 million PIPE investment in NASDAQ-listed SINA Corporation*
  • NYSE-listed WuXi Pharmatech, a leading Chinese R&D outsourcing company, in its announced (and subsequently terminated) acquisition by Charles River Laboratories for US$1.6 billion*
  • NYSE-listed Mindray Medical International Limited, a China-based medical device company, in its US$202 million acquisition of the worldwide patient monitoring business of Datascope, creating the then-third-largest player in the global patient monitoring industry*

* Denotes experience prior to joining Goodwin.


Recognized in The Legal 500 Asia Pacific (2015) as one of the “prominent names in the Asia private equity scene” and noted for his ability to “think outside the box” and “find novel solutions.”

In The News









J.D., 2000
The George Washington University Law School
(with honors)
B.A., 1996
University of California, Los Angeles
(summa cum laude)



Hong Kong SAR
Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique